Subsequent ischemic stroke and tobacco smoking: A secondary analysis of the POINT trial.
Adam Edward LangAdam H de HavenonBrian Mac GroryNils HenningerLiqi ShuKaren L FurieJ Donald EastonAnthony KimS Claiborne JohnstonShadi YaghiPublished in: European stroke journal (2022)
In this post-hoc analysis of the POINT trial we found that the effect of clopidogrel on reducing subsequent ischemic stroke as well as risk of major hemorrhage did not depend on smoking status, indicating that smokers benefit to a similar degree from DAPT as non-smokers.